1005494-34-7

Upstream product

• 98-59-9 p-toluenesulfonyl chloride 
• 621-59-0 isovanillin 
• 78515-24-9 5-formyl-2-methoxyphenyl 4-methylbenzenesulfonate 

Downstream Products

• 865783-95-5 (E)-2-methoxy-5-((2,4,6-trimethoxystyrylsulfonyl)methyl)phenol 
• 1005494-36-9 3-[(p-toluenesulfonyl)oxy]-4-methoxybenzylthioacetic acid 
• 162470-38-4 (3-acetoxy-4-methoxy-phenyl)-acetonitrile 
• 4468-58-0 3-hydroxy-4-methoxyphenylacetonitrile 
• 1005494-35-8 5-chloromethyl-2-methoxyphenyl 4-methylbenzenesulfonate 

Relevant academic research and scientific papers

Targeting RAS-RAF pathway significantly improves antitumor activity of Rigosertib-derived platinum(IV) complexes and overcomes cisplatin resistance

RAS-RAF pathway presents a valuable target for the cancer treatment due to its important roles in the regulation of tumor proliferation, apoptosis and the obtained resistance. To explore such target a RAS/CRAF interference agent, was therefore conjugated

PROCESSES FOR PREPARING (E)-STYRYLBENZYLSULFONE COMPOUNDS AND USES THEREOF FOR TREATING PROLIFERATIVE DISORDERS

Processes for preparing (E)-2,4,6-(Trimethoxystyryl)-3-O-Phosphate Disodium-4-Methoxybenzyl Sulfones and uses thereof as antiproliferative agents, including, for example, anticancer agents, and as radioprotective and chemoprotective agents.

PHARMACEUTICAL COMPOUNDS

This application describes substituted 1,3,4,6,7,11b-hexahydro-benzo(a)quinolizine compounds, pharmaceutical compositions containing them, processes for making them and their therapeutic methods.

Design, synthesis, and biological evaluation of (E)-styrylbenzylsulfones as novel anticancer agents

Cell cycle progression is regulated by cyclins and cyclin-dependent kinases, which are formed at specific stages of the cell cycle and regulate the G1/S and G2/M phase transitions, employing a series of "checkpoints" governed by phosphorylation of their substrates. Tumor development is associated with the loss of these checkpoint controls, and this provides an approach for the development of therapeutic agents that can specifically target tumor cells. Here, we describe the synthesis and SAR of a novel group of cytotoxic molecules that selectively induce growth arrest of normal cells in the G1 phase while inducing a mitotic arrest of tumor cells resulting in selective killing of tumor cell populations with little or no effect on normal cell viability. The broad spectrum of antitumor activity in vitro and xenograft models, lack of in vivo toxicity, and drug resistance suggest potential for use of these agents in cancer therapy.

Covalently linked acceptor - Donor systems based on isoquinoline N-oxide acceptor: Photoinduced electron transfer produces dual-channel luminescent systems that evolve chemically to photohydroxylation of the aromatic donor

Acceptor-donor compounds containing the isoquinoline N-oxide acceptor and (methoxy)nbenzene (n = 0, 1, 2, 3) electron donors were studied. The two chromophores are connected by a CH2 bridging unit. All acceptor-donor compounds exhibi

Photochemical synthesis of 7,8-dioxygenated isoquinoline alkaloids

A new approach to the synthesis of 7,8-dioxygenated tetrahydroisoquinoline alkaloids based on the photo-Fries rearrangement of esters derived from 3-hydroxy-4-methoxy phenylacetonitrile is reported. The procedure was applied to the synthesis of the alkaloid Arizonine and 1-benzyl tetrahydroisoquinoline precursor of cularine and 1,2-berbine alkaloids.